Company news

Genmab A/S news in 2026

Genmab A/S's news releases, calls and decks from 2026, newest first.

View company

Interim Report for the First Nine Months of 2026

November 5, 2026

Genmab A/S Announces Rinatabart Sesutecan (Rina-S) Phase 2 RAINFOLTM-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

October 3, 2026

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

October 3, 2026

Notice to Convene an Extraordinary General Meeting of Genmab A/S

September 8, 2026

Interim Report for the First Half of 2026

August 6, 2026

Genmab Announces Financial Results for the First Half of 2026

August 6, 2026

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026

July 15, 2026

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

July 6, 2026

Genmab A/S has published its Articles of Association

June 17, 2026

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

June 11, 2026

Major Shareholder Announcement

May 8, 2026

Genmab Announces Financial Results for the First Quarter of 2026

May 7, 2026

Genmab A/S Share Capital Reduction

April 17, 2026

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026

April 14, 2026

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

April 13, 2026

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

April 1, 2026

Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab

March 19, 2026

Passing of Genmab A/S’ Annual General Meeting

March 19, 2026

Completion of Share Buy-back Program

March 16, 2026

Transactions in Connection with Share Buy-back Program

March 9, 2026

Correction to Company Announcement No. 13 of March 2, 2026

March 2, 2026

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

February 27, 2026

Genmab to Participate in Upcoming Investor Conferences

February 25, 2026

Capital Increase in Genmab as a Result of Employee Warrant Exercise

February 24, 2026

Notice to Convene the Annual General Meeting of Genmab A/S

February 18, 2026

Genmab Announces Initiation of Share Buy-Back Program

February 17, 2026

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

February 17, 2026

Genmab Publishes 2025 Annual Report

February 17, 2026

Grant of Restricted Stock Units and Warrants to Employees in Genmab

January 29, 2026

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025

January 21, 2026

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

January 16, 2026

Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence

January 7, 2026

Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Calls in 2026

Decks in 2026